Vincenza Pironti

Nov 21, 2024 | themedicinemaker.com | Vincenza Pironti

The pharmaceutical and biopharmaceutical industries are experiencing a surge in demand for sterile manufacturing, driven by the rise of injectable drug products including vaccines, cell and gene therapies, and complex biologics. As part of the production of sterile therapeutics, careful consideration of container formats is needed to ensure their safe and effective delivery.

Jun 26, 2024 | bioprocessintl.com | Cheryl Scott |Vincenza Pironti |Brian Gazaille |Kurt D. Ristroph

Advances related to drug delivery, formulation, and fill–finish have paralleled drug-modality research in recent years. Perhaps inevitably, the newest formulations and devices bring forth a number of technical and operating challenges in areas such as contamination control, standardization (especially for prefilled syringes), lyophilization, serialization, and management of outsourcing/partnering relationships.

May 21, 2024 | biopharminternational.com | Vincenza Pironti

The demand for blow-fill-seal (BFS) technology has significantly increased in recent years because of the rising demand for biologic-based drug products and vaccines. Valued at $2.8 billion in 2022, the BFS technology market is predicted to grow at a compound annual growth rate of 9% until 2031, to reach $6.2 billion (1). Created through automated manufacture, BFS is being explored for unit dose containers for vaccines and other biologic products.